Apogee Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

Ticker: APGE · Form: 10-K · Filed: Mar 5, 2024 · CIK: 1974640

Apogee Therapeutics, Inc. 10-K Filing Summary
FieldDetail
CompanyApogee Therapeutics, Inc. (APGE)
Form Type10-K
Filed DateMar 5, 2024
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Annual Report, Apogee Therapeutics, Biotechnology, SEC Filing

TL;DR

<b>Apogee Therapeutics, Inc. has filed its 2023 annual report (10-K) detailing its business operations and financial standing.</b>

AI Summary

Apogee Therapeutics, Inc. (APGE) filed a Annual Report (10-K) with the SEC on March 5, 2024. Apogee Therapeutics, Inc. filed its 2023 Form 10-K on March 5, 2024. The company's principal executive offices are located at 221 Crescent St., Building 17, Suite 102B, Waltham, MA. Apogee Therapeutics, Inc. was formerly known as Apogee Therapeutics, LLC, with a name change effective April 20, 2023. The company's fiscal year ends on December 31. The filing covers the fiscal year ended December 31, 2023.

Why It Matters

For investors and stakeholders tracking Apogee Therapeutics, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Apogee Therapeutics' business, financial condition, and risk factors for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. The filing includes details on executive compensation, stock options, and significant agreements, offering insights into the company's governance and strategic partnerships.

Risk Assessment

Risk Level: low — Apogee Therapeutics, Inc. shows low risk based on this filing. The risk level is assessed as low because the filing is a standard annual report (10-K) and does not contain immediate, significant negative financial disclosures or operational challenges. It primarily serves to provide a historical overview and fulfill regulatory requirements.

Analyst Insight

Review the detailed financial statements and risk factors within the 10-K to understand Apogee Therapeutics' current financial health and potential future challenges.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Conformed period of report)
  • 2024-03-05 — Filing Date (Filed as of date)
  • 001-41740 — SEC File Number (SEC file number)
  • 24718194 — Film Number (Film number)

Key Players & Entities

  • Apogee Therapeutics, Inc. (company) — Filer name
  • 20231231 (date) — Conformed period of report
  • 20240305 (date) — Filed as of date
  • Waltham, MA (location) — Business address city and state
  • Apogee Therapeutics, LLC (company) — Former company name
  • 20230420 (date) — Date of name change
  • DE (location) — State of incorporation
  • 2836 (industry_code) — Standard Industrial Classification

FAQ

When did Apogee Therapeutics, Inc. file this 10-K?

Apogee Therapeutics, Inc. filed this Annual Report (10-K) with the SEC on March 5, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Apogee Therapeutics, Inc. (APGE).

Where can I read the original 10-K filing from Apogee Therapeutics, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Apogee Therapeutics, Inc..

What are the key takeaways from Apogee Therapeutics, Inc.'s 10-K?

Apogee Therapeutics, Inc. filed this 10-K on March 5, 2024. Key takeaways: Apogee Therapeutics, Inc. filed its 2023 Form 10-K on March 5, 2024.. The company's principal executive offices are located at 221 Crescent St., Building 17, Suite 102B, Waltham, MA.. Apogee Therapeutics, Inc. was formerly known as Apogee Therapeutics, LLC, with a name change effective April 20, 2023..

Is Apogee Therapeutics, Inc. a risky investment based on this filing?

Based on this 10-K, Apogee Therapeutics, Inc. presents a relatively low-risk profile. The risk level is assessed as low because the filing is a standard annual report (10-K) and does not contain immediate, significant negative financial disclosures or operational challenges. It primarily serves to provide a historical overview and fulfill regulatory requirements.

What should investors do after reading Apogee Therapeutics, Inc.'s 10-K?

Review the detailed financial statements and risk factors within the 10-K to understand Apogee Therapeutics' current financial health and potential future challenges. The overall sentiment from this filing is neutral.

Key Dates

  • 2023-12-31: Fiscal Year End — The end of the reporting period for the 10-K filing.
  • 2024-03-05: Filing Date — The date the 10-K was officially submitted to the SEC.
  • 2023-04-20: Name Change — Date Apogee Therapeutics, LLC officially became Apogee Therapeutics, Inc.

Filing Stats: 4,506 words · 18 min read · ~15 pages · Grade level 16 · Accepted 2024-03-05 06:15:46

Key Financial Figures

  • $0.00001 — ch registered Common Stock, par value $0.00001 per share APGE The Nasdaq Global Ma

Filing Documents

Business

Item 1. Business Overview We are a clinical stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Our antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Our two most advanced programs are APG777 and APG808, which we are initially developing for the treatment of AD and COPD, respectively. With our broad pipeline and depth of expertise, we believe we can deliver value and meaningful benefit to patients underserved by today's standard of care. See the section titled "—Recent Developments" for program updates. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. AD is a chronic inflammatory skin disorder that affects approximately 40 million adults and 18 million children in the United States, France, Germany, Italy, Japan, Spain and the United Kingdom, 40% of which have moderate-to-severe disease. Based on our preclinical studies, we believe APG777 can be dosed either every two or every three months in maintenance, which, if our clinical trials are successful, would represent a significant improvement compared to first generation IL-13 antibodies that are dosed every two to four weeks. In August 2023, we announced the dosing of our first participant in our first clinical trial for APG777 in Australia. The APG777 Phase 1 trial is a double-blind, placebo-controlled study in healthy volunteers and consists of a single-ascending dose (SAD) component and a multiple-ascending dose (MAD) component. The trial enrolled 40 healthy adult subjects into three SAD and two MAD cohorts. The primary endpoint is safety and a key secondary endpoint is pharmacokinetics (PK). The Phase 1 tr

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.